Targeting the Immune System for Ischemic Stroke

Stroke is the leading cause of death and disability globally. Two-thirds of stroke survivors are left disabled, requiring assistance in daily living tasks. Currently, treatments for ischemic stroke are limited to clot lysis and/or mechanical removal within a few hours of stroke onset. In addition to the brain injury and cell death that occurs rapidly due to severe cerebral ischemia, a secondary phase of infarct growth is driven by inflammation...